Grand Flight Investment

Grand Flight Investment is an emerging growth private equity firm based in Shanghai, China, specializing in growth-stage and late-stage private equity and venture capital investments. The firm operates with the strategic sponsorship of Far East Horizon (HK.03360), which underpins its robust investment capacity and market reach. Grand Flight Investment actively targets companies poised for significant expansion, focusing on sectors with high growth potential, as demonstrated by its investment in the biopharmaceutical firm HopeMed, founded by Professor Rui-Ping Xiao. The firm frequently engages in collaborative financing efforts, having co-led investment rounds with established partners such as Qiming Venture Partners, indicating a preference for syndicated deals. Its core business model involves generating returns through carefully selected private equity and venture capital placements, aiming to foster the development and scaling of its portfolio companies.